20 likes | 135 Views
This study evaluates the plasma concentration of ONO-2921 following intravenous administration in rats, using HPLC for quantification (mean ± S.E., n=3). Additionally, we investigate the solubility of ONO-2921 when combined with varying concentrations of Malt-β-CD, with the mixture incubated overnight before analysis. The solubility was also determined by HPLC (mean ± S.D., n=3). Our findings provide crucial insights into the pharmacokinetic profile and solubility enhancement of ONO-2921, contributing to its potential therapeutic applications.
E N D
Supplementary Fig. 1. Plasma concentration of ONO-2921 in rats after intravenous administration of ONO-2921 SD2 suspension. The amount of ONO-2921 was determined by HPLC as described in Materials and Methods section. Each value represents the mean ± S.E. (n=3).
Supplementary Fig. 2. Solubility of ONO-2921 in the presence of increasing concentration of Malt-β-CD. ONO-2921 was mixed with Malt-β-CD solution and then the mixture was incubated overnight. ONO-2921 was determined by HPLC method as described in Materials and Methods section. Each value represents the mean ± S.D. (n=3).